The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting

Not Applicable

Completed

• Conditions: Herpes Zoster

• Registration Number: NCT00689013
• Lead Sponsor: University of Tennessee

Brief Summary

The purpose of this study is to determine whether pharmacist-driven patient interventions can have an effect on the number of herpes zoster (Zostavax) vaccinations given in a community pharmacy setting.

Detailed Description

Several studies exist documenting the perception and satisfaction of patients receiving immunizations from pharmacists, as well as the effects of pharmacist involvement in advocating and administering vaccinations. The most well documented studies have been conducted in hospital settings. Undoubtedly, there is enormous opportunity for the community pharmacist to identify potential vaccine recipients, advocate immunization and administer said immunizations to their established patient populations. However, there is a lack of concentrated study in the implementation of immunization services in the community setting and their effects. The investigators intend to evaluate the intervention of pharmacists in an immunization program and the resulting changes in immunization rates.

Study Timeline

• Study Start: 2008-02
• Primary Completion: 2008-03
• Study Completion: 2008-03
• Study First Submitted: 2008-05-21
• Study First Submitted QC: 2008-05-29
• Study First Posted: 2008-06-03
• Status Verified: 2009-04
• Last Update Submitted: 2009-04-22
• Last Update Posted: 2009-04-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

• men and women aged 60 or older without contraindications for the herpes zoster vaccination
• patients who have already experienced one or more episodes of herpes zoster infection were considered for vaccine receipt and study inclusion secondary to CDC ACIP recommendations

Exclusion Criteria

• Patients aged < 60 years
• Anyone who has previously received the herpes zoster vaccine
• Anyone with an allergy to neomycin, gelatin or any other component of the vaccine
• Anyone receiving a live vaccine within 4 weeks
• Anyone with a compromised or weakened immune systems such as those receiving radiation, corticosteroids, or those with HIV/AIDS, cancer in the lymph, bone or blood systems
• Pregnant women or those in close contact with a pregnant woman

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Primary Outcome Measures

Name	Time	Method
To assess the effect of a pharmacist-driven immunization campaign on the rate of Zostavax immunizations in three separate community pharmacy settings	2 months

Secondary Outcome Measures

Name	Time	Method
To evaluate the relative efficacy of specific interventions on the rate of herpes zoster vaccinations	2 months
To evaluate the perception of patients receiving the herpes zoster vaccination as to the role of pharmacists as immunizers	2 months

Trial Locations

Locations (3)

Wilson Pharmacy; 🇺🇸 Johnson City, Tennessee, United States

Marcrom's Pharmacy; 🇺🇸 Manchester, Tennessee, United States

Reeves-Sain Drug Store; 🇺🇸 Murfreesboro, Tennessee, United States